Trial Profile
A Pilot Trial of a WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2022
Price :
$35
*
At a glance
- Drugs Galinpepimut S (Primary) ; Bortezomib; Lenalidomide; Montanide ISA-51; Sargramostim
- Indications Multiple myeloma
- Focus Pharmacodynamics
- Sponsors Sellas Life Sciences Group
- 06 Jan 2020 Planned End Date changed from 1 Apr 2018 to 1 Aug 2020.
- 13 Sep 2018 Results presented in a a SELLAS Life Sciences Group media release.
- 16 Apr 2018 According to a SELLAS Life Sciences Group media release, results from this study was presented at European Society for Blood and Marrow Transplantation (EBMT) 44th Annual Meeting 2018.